{"brief_title": "A Study of DTC in Patients With AIDS and AIDS Related Complex", "brief_summary": "To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents progression from ARC to AIDS or progression of AIDS; and if DTC prolongs survival in AIDS.", "condition": ["HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Ditiocarb sodium"], "criteria": "Inclusion Criteria Concurrent Medication: Allowed: - Zidovudine (AZT). Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - Active opportunistic infection or progressive Kaposi's sarcoma (KS). - Dementia. - Lymphoma. Concurrent Medication: Excluded within 3 weeks of study entry: - Other experimental AIDS therapy. Patients with the following are excluded: - Active opportunistic infection or progressive Kaposi's sarcoma (KS). Patients must be either HIV seropositive or have AIDS or AIDS related complex (ARC) and have life expectancy of at least 6 months.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "AIDS-Related Complex", "mesh_term": ["HIV Infections", "AIDS-Related Complex", "Ditiocarb"], "id": "NCT00002069"}